These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 10602778)
21. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia. Clark RE Leuk Lymphoma; 1995 Oct; 19(3-4):189-95. PubMed ID: 8535209 [TBL] [Abstract][Full Text] [Related]
37. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654 [TBL] [Abstract][Full Text] [Related]
38. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells]. Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468 [TBL] [Abstract][Full Text] [Related]
39. Oligonucleotide N3'-->P5' phosphoramidates as antisense agents. Gryaznov S; Skorski T; Cucco C; Nieborowska-Skorska M; Chiu CY; Lloyd D; Chen JK; Koziolkiewicz M; Calabretta B Nucleic Acids Res; 1996 Apr; 24(8):1508-14. PubMed ID: 8628685 [TBL] [Abstract][Full Text] [Related]